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our next scenario discusses conflicts of inter-
est that may arise through receipt of gifts, sam-
ples or “freebies”. 
SCENARIO
SAmPlES ANd FREEbIES
 you are invited to attend a continuing educa-
tion evening about obesity by a sales represent-
ative for a pet food company that is launching a
new brand of diet food.
What should you do?
RESPONSE
ANdREW kNIgHT
 in an ideal world, all clinical decisions,
including decisions about which drugs, diets
and products to prescribe, would be purely
rational and evidence-based, to maximise opti-
mal patient outcomes. the reality, of course, is
that this ideal is subverted to varying degrees
by factors ranging from relatively benign to con-
siderably less so. More benign examples include
lack of certainty about a diagnosis, or of certain
evidence about a proposed treatment’s efficacy,
in which case decisions are made on the basis
of probabilities rather than certainties; and gen-
uine financial limitations of owners, which result
in the selection of a suboptimal, but cheaper,
treatment option. Less benign influences on the
prescribing process include overemphasis on
the interests of the treating veterinarian or prac-
tice in maximising profit, or on ease of treatment
(e.g. minimising hospitalised caseloads over
the weekend), or on trialling a therapy with less
evidence of efficacy, in which a clinician has a
particular interest. And a particularly prominent
area of concern – which is related to this case 
– is the attempted subversion of treatment deci-
sions by the commercial interests of companies
supplying pharmaceuticals, diets or other veter-
inary products.
Of course such companies exist partly to 
create and distribute products that make a major 
contribution to animal health and welfare, and in 
doing so make important, positive contributions 
to society. However, they also have a duty to their 
shareholders to maximise profits, which occurs 
when their products are used as widely as pos-
sible – regardless of the degree to which their 
products are actually clinically superior to alter-
native treatment options. this can create a strong 
interest within such companies in influencing pre-
scribing decisions. After all, these companies do 
operate within a competitive environment. they 
succeed or go bankrupt in a corporate version 

7.17 Continuing education events are often 
sponsored by pharmaceutical or food companies, 
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of the “survival of the fittest”, based on a com-
bination of the effectiveness of their products, 
and perhaps even more importantly, the extent to 
which they can successfully influence clinicians 
to use them, and clients to request them.
Companies supplying pharmaceuticals, pre-
scription diets or other healthcare products are 
known to seek to influence prescribing decisions 
in a variety of ways. through sponsorship or gifts 
they seek to build relationships and influence with 
clinicians. they may sponsor continuing educa-
tion events, and even the travel and accommo-
dation costs of clinicians. they may also arrange 
such events themselves, such as in this example 
relating to obesity. Such sponsorship is very sig-
nificant, particularly within the world of human 
healthcare, where the financial stakes are even 
higher. As d’Arcy and Moyniham (2009) reported, 
“the pharmaceutical industry is an extremely 
important source of funding for continuing medi-
cal education – 35% of the estimated US$9–14 
billion that industry spends each year on phar-
maceutical marketing goes towards educational 
support.” Companies may also target students, as 
occurs when suppliers of prescription veterinary 
diets offer discounted pet food to students in vet-
erinary schools.
Even more disturbing is the subversion of 
scientific evidence by such companies. it is well 
understood within the scientific world that studies 
of the effectiveness of a new treatment are more 
likely to show a positive result when funded by 
companies with a commercial interest, than when 
funded by independent sources such as gov-
ernment agencies, charities or universities. Such 
studies more often have favourable efficacy results 
and overall conclusions, and are less likely to show 
evidence of harm, than non-industry-sponsored 
studies (Lundh, et al. 2012).
Goldacre (2009, 2012) has described at length 
the various methodological manipulations that 
occur within such studies that predispose them 
to outcomes more likely to be favourable to the 
industry funder. this problem is pervasive within 
science. in a survey of scientists randomly sourced 
from databases maintained by the National insti-
tutes of Health’s Office of Extramural Research, 
15.5% of all 3247 respondents reported changing 
the design, methodology or results of a study in 
response to pressure from a funding source (Mar-
tinson, et al. 2005).
tempting though it might appear at first glance, 
the solution to problems such as these is not to 
ban all industry involvement in scientific studies 
or educational events. As d’Arcy and Moyniham 
(2009) stated, because sponsorship of continu-
ing educational events is so substantial, “if phar-
ma-sponsored education is no longer allowed, we 
may witness tomorrow’s doctors practicing yes-
terday’s medicine.” Similarly, a great deal of sci-
entific work relating to the development of new 
therapeutics would not occur, without industry 
sponsorship.
However, we must recognise that the primary 
interests of industry are not in advancing science 
or patient welfare, but in advancing their com-
mercial competitiveness. Accordingly, we must 
demand absolute transparency with respect to 
their generation of scientific results, and we must 
subject claims about the safety and efficacy of 
their products in scientific studies or educational 
events to very rigorous critical scrutiny. in this 
particular case relating to the obesity presenta-
tion, you should attend if possible, but you should 
closely scrutinise the claims made about the effi-
cacy of the new company diet, and you should 
examine the evidence in support of those claims, 
paying particular attention to the methodological 
design of any supporting studies.
in order for such increased scrutiny and crit-
ical review to become more firmly embedded 
within the culture of medicine – both human and 
veterinary – scientists and policymakers must be 
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this pervasive problem, and about how to crit-
ically assess evidence, and particularly study 
methodologies, for sources of bias, and about 
how to minimise these through good experimental 
design. Such training should be included within 
the curricula of veterinary schools, and should be 
made available through continuing education to 
veterinarians.
whilst being aware of, and concerned to
reduce, any possible conflicts of interest may 
help to mitigate negative outcomes there may be 
some benefits to associations with pharmaceu-
tical or drug companies. if veterinary practices 
are not aware of new treatments they will not be 
used, even if they are the best available. Compa-
nies, partly driven by self-interest, aim to increase 
awareness of their products through advertising 
and other promotional efforts. Free samples 
may enable discounted treatments for financially 
compromised clients, or allow a greater under-
standing of a product, for example food or routine 
treatments, if they are used on the veterinarian’s 
own animals.
CoNFlICTS oF INTEREST
What do you think?
one What do you think are the most 
important ethical considerations for 
whether there should be restrictions 
on sponsorship of student, 
veterinary and nursing training 
events by pharmaceutical or food 
manufacturers or other veterinary 
companies?
one Which, if any, restrictions would you 
support?

7.18 Would you consider restrictions on 
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